# Effect of LY2062430 on the Progression of Alzheimer's Disease

> **NCT00905372** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1000 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** LY2062430
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00905372
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2012-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00905372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00905372, "Effect of LY2062430 on the Progression of Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00905372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*